IN2013MU00848A - - Google Patents

Info

Publication number
IN2013MU00848A
IN2013MU00848A IN848MU2013A IN2013MU00848A IN 2013MU00848 A IN2013MU00848 A IN 2013MU00848A IN 848MU2013 A IN848MU2013 A IN 848MU2013A IN 2013MU00848 A IN2013MU00848 A IN 2013MU00848A
Authority
IN
India
Prior art keywords
anagliptin
intermediates
preparation
present
provides process
Prior art date
Application number
Other languages
English (en)
Inventor
Mahadev Kadam Suresh
Parsottam Kansagra Bipin
Nilkanth Bhadane Shailendra
Prakashrao Patil Jayant
Kantilal Kale Shrikrishna
Original Assignee
Glenmark Generics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Generics Ltd filed Critical Glenmark Generics Ltd
Priority to IN848MU2013 priority Critical patent/IN2013MU00848A/en
Priority to PCT/IN2014/000132 priority patent/WO2014147640A2/en
Publication of IN2013MU00848A publication Critical patent/IN2013MU00848A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
IN848MU2013 2013-03-19 2014-02-28 IN2013MU00848A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN848MU2013 IN2013MU00848A (es) 2013-03-19 2014-02-28
PCT/IN2014/000132 WO2014147640A2 (en) 2013-03-19 2014-02-28 Process for the preparation of anagliptin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN848MU2013 IN2013MU00848A (es) 2013-03-19 2014-02-28

Publications (1)

Publication Number Publication Date
IN2013MU00848A true IN2013MU00848A (es) 2015-05-01

Family

ID=51581562

Family Applications (1)

Application Number Title Priority Date Filing Date
IN848MU2013 IN2013MU00848A (es) 2013-03-19 2014-02-28

Country Status (2)

Country Link
IN (1) IN2013MU00848A (es)
WO (1) WO2014147640A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103896951A (zh) * 2014-03-26 2014-07-02 上海朴颐化学科技有限公司 2-甲基-吡唑并[1,5-a]嘧啶-6-羧酸的合成方法
CN105315284A (zh) * 2014-07-23 2016-02-10 上海医药工业研究院 阿拉格列汀中间体的制备方法
CN108358935A (zh) * 2018-03-12 2018-08-03 南安市创培电子科技有限公司 一种医药中间体2-甲基-吡唑并[1,5-a]嘧啶-6-羧酸的合成方法
CN108341782A (zh) * 2018-03-30 2018-07-31 南京哈柏医药科技有限公司 3-氨基-5-甲基吡唑的合成工艺
SI3773589T1 (sl) 2018-04-03 2024-03-29 Blueprint Medicines Corporation Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo
CN110003218B (zh) * 2019-03-26 2020-07-31 杭州瀚康生物医药科技有限公司 阿拉格列汀中间体的制备方法
WO2021136491A1 (zh) * 2019-12-31 2021-07-08 石药集团中奇制药技术（石家庄）有限公司 一种二肽基肽酶iv抑制剂的晶型及其制备方法和用途
CA3203970A1 (en) 2020-12-04 2022-06-09 Blueprint Medicines Corporation Method of preparing pralsetinib
CN115650984A (zh) * 2022-09-07 2023-01-31 江苏君若药业有限公司 一种安那格列汀的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067509A1 (ja) * 2003-01-31 2004-08-12 Sanwa Kagaku Kenkyusho Co., Ltd. ジペプチジルペプチダーゼivを阻害する化合物

Also Published As

Publication number Publication date
WO2014147640A2 (en) 2014-09-25
WO2014147640A3 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
MX2021014955A (es) Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos.
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12016501763A1 (en) Multispecific antibodies
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
SI3380530T1 (sl) Izboljšan postopek za pripravo sugamadeksa in njegovih intermediatov
MY176285A (en) Anti-fcrh5 antibodies
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MY176855A (en) Anti-jagged1 antibodies and methods of use
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
IN2013MU00848A (es)
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
IN2012MU03723A (es)
IN2014DN09450A (es)
IN2013MU00646A (es)
MX2020007742A (es) Procesos para preparar fluorocetolidos.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
IN2013MU01113A (es)
NZ721832A (en) Solid forms of tenofovir
MX2015012902A (es) Sintesis de ent-progesterona e intermediarios de la misma.
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.